Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
♫ Tuesday, May 14th, 2024SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2024 and provided a general business update.
Continue reading here:
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update